Structure via PubChem · Public domain (PubChem)
mavoglurant
Sign in to saveAlso known as AFQ056, AFQ-056
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5).
Chemical data
- Formula
- C19H23NO3
- Molecular weight
- 313.4 g/mol
- IUPAC name
- methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate
- SMILES
- CC1=CC(=CC=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O
- InChIKey
- ZFPZEYHRWGMJCV-ZHALLVOQSA-N
- XLogP
- 2.9
- Polar surface area
- 49.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- obsessive-compulsive disorder, liver disease, cocaine dependence, gastroesophageal reflux disease
via ChEMBL · EBI
Wikidata facts
- Mass
- 313.168
Show 4 more facts
- chemical formula
- C₁₉H₂₃NO₃
- isomeric SMILES
- CC1=CC=CC(=C1)C#C[C@@]2(CCC[C@@H]3[C@H]2CCN3C(=O)OC)O
- canonical SMILES
- CC1=CC=CC(=C1)C#CC2(CCCC3C2CCN3C(=O)OC)O
- World Health Organisation international non-proprietary name
- mavoglurant
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5).
Mavoglurant was under development by Novartis and reached phase II and phase III clinical trials. Phase IIb/III dose finding and evaluation trials for fragile X-syndrome were discontinued by the end of 2014. Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome. Mavoglurant was also in phase II clinical trials for Levodopa-induced dyskinesia. In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now. Novartis was conducting a clinical trial with this drug on obsessive–compulsive disorder.
Excerpted from Wikipedia’s “mavoglurant” article, available under the CC BY-SA 4.0 licence.